Pub Date : 2019-08-13DOI: 10.29328/JOURNAL.ACH.1001018
Kanako Saito, Y. Hishiki, Hakuo Takahashi
Monitoring and regulating blood pressure (BP) levels are crucial in the management of cerebral and cardiovascular diseases [1]. However, BP is always luctuating depending on the effects of environmental factors on autonomic nervous system activity and diurnal variations [2]. Therefore, frequent and repeated measurement of BP under conditions of minimum environmental stress is recommended for the assessment of BP in individuals. For this purpose, fully automated BP monitors are increasingly replacing standard mercury sphygmomanometers [3]. No speci ic training is required to use these monitors and they avoid observer error. Moreover, mercury sphygmomanometers are no longer distributed on the market due to the possibility of mercury pollution. Furthermore, the white-coat effect is also minimized as healthcare professionals are not present during measurements.
{"title":"Validation of the Omron HBP-9031C blood pressure monitor for clinics and hospitals according to the ANSI/AAMI/ISO 81060-2:2013 protocol","authors":"Kanako Saito, Y. Hishiki, Hakuo Takahashi","doi":"10.29328/JOURNAL.ACH.1001018","DOIUrl":"https://doi.org/10.29328/JOURNAL.ACH.1001018","url":null,"abstract":"Monitoring and regulating blood pressure (BP) levels are crucial in the management of cerebral and cardiovascular diseases [1]. However, BP is always luctuating depending on the effects of environmental factors on autonomic nervous system activity and diurnal variations [2]. Therefore, frequent and repeated measurement of BP under conditions of minimum environmental stress is recommended for the assessment of BP in individuals. For this purpose, fully automated BP monitors are increasingly replacing standard mercury sphygmomanometers [3]. No speci ic training is required to use these monitors and they avoid observer error. Moreover, mercury sphygmomanometers are no longer distributed on the market due to the possibility of mercury pollution. Furthermore, the white-coat effect is also minimized as healthcare professionals are not present during measurements.","PeriodicalId":90435,"journal":{"name":"Annals of clinical and experimental hypertension","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79262643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-06-27DOI: 10.29328/JOURNAL.ACH.1001016
A. Berezin, A. Berezin
{"title":"Circulating platelet-derived vesicle in atrial fibrillation","authors":"A. Berezin, A. Berezin","doi":"10.29328/JOURNAL.ACH.1001016","DOIUrl":"https://doi.org/10.29328/JOURNAL.ACH.1001016","url":null,"abstract":"","PeriodicalId":90435,"journal":{"name":"Annals of clinical and experimental hypertension","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81012450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-04-03DOI: 10.29328/JOURNAL.ACH.1001015
L. Alcocer, H. Álvarez-López, G. Borrayo-Sánchez, E. Cardona-Muñoz, Adolfo Chavez-Mendozaa, Enrique Díaz y Díaz, J. M. Enciso-Munoz, Hector Galvan-Osegueraα, E. Gómez-Álvarez, P. Gutiérrez-Fajardo, H. H. Y. Hernández, Francisco Javier Leon-Hernandez, J. A. Magaña-Serrano, J. Z. Parra-Carrillo, M. Rosas-Peralta
Today, Mexico has more than 130 million inhabitants; 85 millions of them are adults of 20 or more years old. The population pyramid is still one of base wider and this base corresponds to adults younger than 54 years old. Despite predictions made 20 years ago, about a transformation of the population pyramid shape to a mushroom shape as a consequence of more life expected and adult population growth; this change has not been occurred. Hypertension has become the biggest challenge of noncommunicable chronic diseases to public health in Mexico. Around 30% of adult Mexican population has hypertension; 75% of them have less than 54 years old (in productive age); 40% of them are unaware but only 50% of aware hypertensive population takes drugs and, 50% of them are controlled (< 140/90 mmHg). Cardiovascular risk factors including hypertension, dyslipidemia, obesity, and diabetes often cohabit in the same person and are magnifi ed one to another in terms of common pathophysiological pathways. Atherosclerosis, arrhythmias, stroke and heart failure are common and are the fi nal pathologic end-points and explains why cardiovascular diseases occupy fi rst place in mortality in Mexico and worldwide. The costs of care for these diseases are billionaires and if we do not generate appropriate strategies, their global impact can become a high threat to social development of the country. The life style like nutrition, sports habits of the Mexicans must be emphasized; there is poor education about this crucial topic. This position paper is focused on the principal controversies and strategies to be developed by all, government, society, physicians, nurses, patients and all people related with healthcare of hypertension, in order to confront this huge public health problem in Mexico. Review Article
{"title":"Hypertension as a persistent public health problem. A position paper from Alliance for a Healthy Heart, Mexico","authors":"L. Alcocer, H. Álvarez-López, G. Borrayo-Sánchez, E. Cardona-Muñoz, Adolfo Chavez-Mendozaa, Enrique Díaz y Díaz, J. M. Enciso-Munoz, Hector Galvan-Osegueraα, E. Gómez-Álvarez, P. Gutiérrez-Fajardo, H. H. Y. Hernández, Francisco Javier Leon-Hernandez, J. A. Magaña-Serrano, J. Z. Parra-Carrillo, M. Rosas-Peralta","doi":"10.29328/JOURNAL.ACH.1001015","DOIUrl":"https://doi.org/10.29328/JOURNAL.ACH.1001015","url":null,"abstract":"Today, Mexico has more than 130 million inhabitants; 85 millions of them are adults of 20 or more years old. The population pyramid is still one of base wider and this base corresponds to adults younger than 54 years old. Despite predictions made 20 years ago, about a transformation of the population pyramid shape to a mushroom shape as a consequence of more life expected and adult population growth; this change has not been occurred. Hypertension has become the biggest challenge of noncommunicable chronic diseases to public health in Mexico. Around 30% of adult Mexican population has hypertension; 75% of them have less than 54 years old (in productive age); 40% of them are unaware but only 50% of aware hypertensive population takes drugs and, 50% of them are controlled (< 140/90 mmHg). Cardiovascular risk factors including hypertension, dyslipidemia, obesity, and diabetes often cohabit in the same person and are magnifi ed one to another in terms of common pathophysiological pathways. Atherosclerosis, arrhythmias, stroke and heart failure are common and are the fi nal pathologic end-points and explains why cardiovascular diseases occupy fi rst place in mortality in Mexico and worldwide. The costs of care for these diseases are billionaires and if we do not generate appropriate strategies, their global impact can become a high threat to social development of the country. The life style like nutrition, sports habits of the Mexicans must be emphasized; there is poor education about this crucial topic. This position paper is focused on the principal controversies and strategies to be developed by all, government, society, physicians, nurses, patients and all people related with healthcare of hypertension, in order to confront this huge public health problem in Mexico. Review Article","PeriodicalId":90435,"journal":{"name":"Annals of clinical and experimental hypertension","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82487379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-28DOI: 10.29328/JOURNAL.ACH.1001014
Lizette Arizmendi-Ocampo, M. Peralta, D. Morales, Alejandro Espinosa, A. Rodríguez, E. Árias, Carlos Riera kinkel, Guadalupe Castro Martínez, J. A. Magaña-Serrano
{"title":"Heart Failure with preserved Ejection Fraction (HFpEF); A Mexican cohort from Mexican Institute of Social Security (IMSS)","authors":"Lizette Arizmendi-Ocampo, M. Peralta, D. Morales, Alejandro Espinosa, A. Rodríguez, E. Árias, Carlos Riera kinkel, Guadalupe Castro Martínez, J. A. Magaña-Serrano","doi":"10.29328/JOURNAL.ACH.1001014","DOIUrl":"https://doi.org/10.29328/JOURNAL.ACH.1001014","url":null,"abstract":"","PeriodicalId":90435,"journal":{"name":"Annals of clinical and experimental hypertension","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87492177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-11-23DOI: 10.29328/journal.ach.1001013
Ibrahim* M Mohsen
{"title":"Strategic Plans for Diagnosis, Treatment & Control of Hypertension","authors":"Ibrahim* M Mohsen","doi":"10.29328/journal.ach.1001013","DOIUrl":"https://doi.org/10.29328/journal.ach.1001013","url":null,"abstract":"","PeriodicalId":90435,"journal":{"name":"Annals of clinical and experimental hypertension","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87775519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-07-17DOI: 10.29328/JOURNAL.ACH.1001010
M. Rosas-Peralta, G. Borrayo-Sánchez, Erick Ramírez-Árias, Gladys Marcela Jiménez-Genchi, Martha Hernández-González, Rafael Barraza-Felix, Lidia Evangelina Betacourt-Hernández, R. Camacho-Casillas, Rodolfo Parra-Michel, Hector Chapa, José de Jesús Arríaga-Dávila
Atherosclerotic cardiovascular disease (ASCVD) is globally defi ned as coronary heart disease, cerebrovascular disease, or peripheral arterial disease presumed to be of atherosclerotic origin and it is the leading cause of morbidity and mortality for individuals with or without diabetes and is the largest contributor to the direct and indirect catastrophic costs of cardiovascular disorder. Very common conditions coexisting into the cardiovascular risk (e.g., obesity, hypertension, diabetes and dyslipidemia) are clear risk factors for ASCVD, and diabetes itself confers independent risk. Numerous studies have shown the effi cacy of controlling individual cardiovascular risk factors in preventing or slowing ASCVD in people with these disorders. In other words it is not enough control one risk factor. We need to develop novel strategies to detect and control all of them at the same time. Thus, large benefi ts are seen when multiple cardiovascular risk factors are addressed simultaneously. Under the current paradigm of aggressive risk factor modifi cation in patients with cardiovascular risk, there is evidence that measures of 10-year coronary heart disease (CHD) risk among U.S. adults with cardiovascular risk have improved signifi cantly over the past decade and that ASCVD morbidity and mortality have decreased. In Mexico the Mexican Institute of Social Security is implementing new strategies of primary and secondary prevention in order to confront this pandemic.
{"title":"Cardiovascular risk reduction: Past, present and future in Mexico","authors":"M. Rosas-Peralta, G. Borrayo-Sánchez, Erick Ramírez-Árias, Gladys Marcela Jiménez-Genchi, Martha Hernández-González, Rafael Barraza-Felix, Lidia Evangelina Betacourt-Hernández, R. Camacho-Casillas, Rodolfo Parra-Michel, Hector Chapa, José de Jesús Arríaga-Dávila","doi":"10.29328/JOURNAL.ACH.1001010","DOIUrl":"https://doi.org/10.29328/JOURNAL.ACH.1001010","url":null,"abstract":"Atherosclerotic cardiovascular disease (ASCVD) is globally defi ned as coronary heart disease, cerebrovascular disease, or peripheral arterial disease presumed to be of atherosclerotic origin and it is the leading cause of morbidity and mortality for individuals with or without diabetes and is the largest contributor to the direct and indirect catastrophic costs of cardiovascular disorder. Very common conditions coexisting into the cardiovascular risk (e.g., obesity, hypertension, diabetes and dyslipidemia) are clear risk factors for ASCVD, and diabetes itself confers independent risk. Numerous studies have shown the effi cacy of controlling individual cardiovascular risk factors in preventing or slowing ASCVD in people with these disorders. In other words it is not enough control one risk factor. We need to develop novel strategies to detect and control all of them at the same time. Thus, large benefi ts are seen when multiple cardiovascular risk factors are addressed simultaneously. Under the current paradigm of aggressive risk factor modifi cation in patients with cardiovascular risk, there is evidence that measures of 10-year coronary heart disease (CHD) risk among U.S. adults with cardiovascular risk have improved signifi cantly over the past decade and that ASCVD morbidity and mortality have decreased. In Mexico the Mexican Institute of Social Security is implementing new strategies of primary and secondary prevention in order to confront this pandemic.","PeriodicalId":90435,"journal":{"name":"Annals of clinical and experimental hypertension","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87670023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-07-17DOI: 10.29328/journal.ach.1001011
Samuel Seriki A
{"title":"Role of the Kidneys in the Regulation of Intra-and Extra-Renal Blood Pressure","authors":"Samuel Seriki A","doi":"10.29328/journal.ach.1001011","DOIUrl":"https://doi.org/10.29328/journal.ach.1001011","url":null,"abstract":"","PeriodicalId":90435,"journal":{"name":"Annals of clinical and experimental hypertension","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77248183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nsini A Umoh, Robin K Walker, Richard M Millis, Mustafa Al-Rubaiee, Pandu R Gangula, Georges E Haddad
CGRP and specific CGRP receptors are found in the heart where they produce positive-inotropic and anti-apoptotic effects, key adaptations to exercise and cardiovascular disease. PI3K/Akt and MAPK signaling imbalances are associated with cardiomyocyte pathologies; however, the effects of CGRP on these pathways are unclear. Therefore, we hypothesized that CGRP modulates inotropic and apoptotic adaptations of cardiomyocytes by regulating PI3K/Akt and MAPK/ERK signaling balances. We treated cardiomyocytes with combinations of CGRP, PI3K/Akt and MAPK signaling agonists and antagonists. We evaluated expression of the mRNA and proteins levels of survival signaling molecules related to the PI3K/Akt and MAPK and measured apoptosis by caspase 3/7 activity. CGRP1-37 decreased Akt, NFκB, SOD-3 and increased ERK1/2 and p38 MAPK expressions, which was antagonized by CGRP8-37. Akt-negative construct transfection, Ad.Akt(K179M), inhibited the CGRP1-37-induced increment in MAPK expressions. A PI3K-antagonist treatment with LY294002 or CGRP1-37/Ad.Akt(K179M) co-treatment alleviated the CGRP-increased caspase activity and -decrements in SOD-3. These findings demonstrate a CGRP negative effect on the PI3K/Akt signaling pathway and CGRP receptor-induced crosstalk between PI3K/Akt and MAPK in normal cardiomyocytes. Future studies to differentiate CGRP effects on intracellular signal transduction mechanisms in pathological conditions will elucidate the significance of CGRP in, and provide novel therapeutic targets for, heart failure.
{"title":"Calcitonin Gene-Related Peptide Regulates Cardiomyocyte Survival through Regulation of Oxidative Stress by PI3K/Akt and MAPK Signaling Pathways.","authors":"Nsini A Umoh, Robin K Walker, Richard M Millis, Mustafa Al-Rubaiee, Pandu R Gangula, Georges E Haddad","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>CGRP and specific CGRP receptors are found in the heart where they produce positive-inotropic and anti-apoptotic effects, key adaptations to exercise and cardiovascular disease. PI3K/Akt and MAPK signaling imbalances are associated with cardiomyocyte pathologies; however, the effects of CGRP on these pathways are unclear. Therefore, we hypothesized that CGRP modulates inotropic and apoptotic adaptations of cardiomyocytes by regulating PI3K/Akt and MAPK/ERK signaling balances. We treated cardiomyocytes with combinations of CGRP, PI3K/Akt and MAPK signaling agonists and antagonists. We evaluated expression of the mRNA and proteins levels of survival signaling molecules related to the PI3K/Akt and MAPK and measured apoptosis by caspase 3/7 activity. CGRP<sub>1-37</sub> decreased Akt, NFκB, SOD-3 and increased ERK1/2 and p38 MAPK expressions, which was antagonized by CGRP<sub>8-37</sub>. Akt-negative construct transfection, Ad.Akt(K179M), inhibited the CGRP<sub>1-37</sub>-induced increment in MAPK expressions. A PI3K-antagonist treatment with LY294002 or CGRP<sub>1-37</sub>/Ad.Akt(K179M) co-treatment alleviated the CGRP-increased caspase activity and -decrements in SOD-3. These findings demonstrate a CGRP negative effect on the PI3K/Akt signaling pathway and CGRP receptor-induced crosstalk between PI3K/Akt and MAPK in normal cardiomyocytes. Future studies to differentiate CGRP effects on intracellular signal transduction mechanisms in pathological conditions will elucidate the significance of CGRP in, and provide novel therapeutic targets for, heart failure.</p>","PeriodicalId":90435,"journal":{"name":"Annals of clinical and experimental hypertension","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251564/pdf/nihms581689.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32884739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：